Lurbinectedin (PM01183), an active compound in platinum-resistant/refractory ovarian cancer (PRROC) patients: Results of a two-stage, controlled phase II study.
Andres Poveda
Honoraria - PharmaMar
Dominique Berton-Rigaud
No relevant relationships to disclose
Isabelle Laure Ray-Coquard
Consultant or Advisory Role - PharmaMar; Roche
Honoraria - PharmaMar; Roche
Jérôme Alexandre
Honoraria - PharmaMar
Magali Provansal
No relevant relationships to disclose
Arturo Soto
Employment or Leadership Position - PharmaMar
Stock Ownership - PharmaMar
Carmen Maria Kahatt
Employment or Leadership Position - PharmaMar
Stock Ownership - PharmaMar
Sergio A. Szyldergemajn
Employment or Leadership Position - PharmaMar
Stock Ownership - PharmaMar
Antonio Nieto
Employment or Leadership Position - PharmaMar
Stock Ownership - PharmaMar
Cristian Fernandez
Employment or Leadership Position - PharmaMar
Stock Ownership - PaarmaMar
Eva Guerra Alia
No relevant relationships to disclose
Antonio Casado
No relevant relationships to disclose
Antonio Gonzalez-Martin
Consultant or Advisory Role - PharmaMar
Jose Maria Del Campo
No relevant relationships to disclose